Video met Prof. Dr. Martin Reck:
Update CheckMate 9LA data live van de ASCO 2024
In deze video (03:51 min) bespreekt longarts Prof. Dr. Martin Reck (Duitsland) de vijfjaarsupdate van de CM9LA studie studie die hij presenteerde op de ASCO 2024.3
Referenties:
1. SmPC nivolumab
2. SmPC ipilimumab
3. Reck M et al, Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial, European Journal of Cancer, (2024) doi:https://doi.org/10.1016/j.ejca.2024.114296
4. Paz-Ares L et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(2):198-211.
5. Carbone et al. J Immunother Cancer 2024 Feb 12;12(2):e008189
7356-NL-2400060
icon below, scroll down and tap 'Add to Homescreen'.
Click 'Add' to install the app on your iPad.